原发性骨髓纤维化:2021年诊断、风险分层与管理更新
本文综述原发性骨髓纤维化(PMF)的诊断、预后分层与治疗进展。诊断以骨髓形态为主,JAK2/CALR/MPL突变约见于90%患者。新预后系统GIPSS和MIPSS70+ v2.0分别基于遗传学和临床因素分层。治疗按风险分层选择观察、临床试验或异基因移植,非移植患者按贫血、脾大、症状选用药物。
要点
- 诊断以骨髓形态为主,JAK2/CALR/MPL突变约90%支持但不必需。
- SRSF2、ASXL1、U2AF1-Q157突变独立预测生存差,RAS/CBL预测芦可替尼耐药。
- 低/极低危观察,高危/极高危首选异基因移植,中危参加临床试验。
核心结论
- PMF诊断依赖骨髓形态,分子标志约90%支持但非必需。
- GIPSS和MIPSSv2新预后系统分别基于遗传学和临床因素进行风险分层。
- 治疗按风险分层:低危观察,高危移植,中危临床试验。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- JAK2、CALR或MPL突变约见于90%的PMF患者。
- 约15%的ET或PV患者可进展为PMF样表型(post-ET/PV MF)。
- SRSF2、ASXL1、U2AF1-Q157突变独立预测PMF生存差。
- RAS/CBL突变预测对芦可替尼治疗耐药。
- 不良核型包括-7、inv(3)、i(17q)、+21、+19、12p-和11q-。
关键数值与推荐
- GIPSS仅基于突变和核型,分4个风险类别。
- MIPSSv2包括临床风险因素,分5个风险类别。
- MIPSSv2低/极低危10年生存率56%-92%。
- MIPSSv2高/极高危10年生存率0%-13%。
- 中危患者10年生存率30%。
临床怎么用
- 低/极低危观察;高/极高危首选异基因造血干细胞移植。
- 中危治疗需求者建议参加临床试验。
- 非移植患者贫血用雄激素、泼尼松、沙利度胺或达那唑。
- 症状性脾大用羟基脲或芦可替尼;体质性症状用芦可替尼。
- 芦可替尼失败后可用fedratinib;难治性脾大考虑脾切除。
局限性
- 本文为综述,未报告系统检索策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations. Additional disease features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, leukemic progression, and shortened survival. DIAGNOSIS: Bone marrow morphology is the primary basis for diagnosis. Presence of JAK2, CALR, or MPL mutation, expected in around 90% of the patients, is supportive but not essential for diagnosis; these mutations are also prevalent in the closely related MPNs, namely polycythemia vera (PV) and essential thrombocythemia (ET). The 2016 World Health Organization classification system distinguishes "prefibrotic" from "overtly fibrotic" PMF; the former might mimic ET in its presentation. Furthermore, approximately 15% of patients with ET or PV might progress into a PMF-like phenotype (post-ET/PV MF) during their clinical course. ADVERSE MUTATIONS: SRSF2, ASXL1, and U2AF1-Q157 mutations predict inferior survival in PMF, independent of each other and other risk factors. RAS/CBL mutations predicted resistance to ruxolitinib therapy. ADVERSE KARYOTYPE: Very high risk abnormalities include -7, inv (3), i(17q), +21, +19, 12p-, and 11q-. RISK STRATIFICATION: Two new prognostic systems for PMF have recently been introduced: GIPSS (genetically-inspired prognostic scoring system) and MIPSS70+ version 2.0 (MIPSSv2; mutation- and karyotype-enhanced international prognostic scoring system). GIPSS is based exclusively on mutations and karyotype. MIPSSv2 includes, in addition, clinical risk factors. GIPSS features four and MIPSSv2 five risk categories. RISK-ADAPTED THERAPY: Observation alone is advised for MIPSSv2 "low" and "very low" risk disease (estimated 10-year survival 56%-92%); allogeneic hematopoietic stem cell transplant (AHSCT) is the preferred treatment for "very high" and "high" risk disease (estimated 10-year survival 0%-13%); treatment-requiring patients with intermediate-risk disease (estimated 10-year survival 30%) are best served by participating in clinical trials. In non-transplant candidates, conventional treatment for anemia includes androgens, prednisone, thalidomide, and danazol; for symptomatic splenomegaly, hydroxyurea and ruxolitinib; and for constitutional symptoms, ruxolitinib. Fedratinib, another JAK2 inhibitor, has now been FDA-approved for use in ruxolitinib failures. Splenectomy is considered for drug-refractory splenomegaly and involved field radiotherapy for non-hepatosplenic EMH and extremity bone pain. NEW DIRECTIONS: A number of new agents, alone or in combination with ruxolitinib, are currently under investigation for MF treatment (ClinicalTrials.gov); preliminary results from some of these clinical trials were presented at the 2020 ASH annual meeting and highlighted in the current document.
引用
- Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020. PMID: 33197049. doi:10.1002/ajh.26050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。